Nuclea Biotechnologies About Us Disease Areas Technology News Contact Us Links
Technology

Antibodies

 

Biorepository and Bioinformatics

Antibodies

 

Nuclea has developed a number of pan antibodies and specific antibodies that greatly simplify and accelerate the drug discovery processes in the tyrosine kinase (TK) pathway. TK's are among the most promising targets for new drug discovery in the oncology arena. Nuclea’s antibodies make possible the rapid identification of proteins that play significant roles in disease, many of which may become novel drug targets or diagnostic markers.

Receptor Pan-Tyrosine Kinase Antibody

Nuclea had developed a novel pan-RTK antibody useful for researching other receptor tyrosine kinase oncoproteins that might participate in tumor pathogenesis. RTKs that may be involved with tumor development may also be explored with this antibody.

Nuclea’s antibody is a rabbit anti-pan-PI3 kinase antibody that recognizes any protein that is phosphorylated on the serine, threonine, or tyrosine residues. It can be used for both immunoprecipitations and Western Blots. This antibody is covered by U.S. Patent No. 7,354,725 B2; additional patents are pending.

Receptor Pan-MAPKAP Kinase Antibody

MAPKAP kinases are similar to Rsk kinases (Rsk1, Rsk2, and Rsk3, also known as MAPKAP kinases 1a, 1b, and 1c), which are activated by mitogen-signaling pathways. Following activation, Rsk translocates to the nucleus; Rsk1 phosphorylates Ser133 of CREB, activating it as a transcription factor, while Rsk2 phosphorylates Ser10 of histone H3, a critical step in the stimulation of immediate-early gene expression. Nuclea has developed a novel anti-MAPKAP antibody useful for researching proteins in this pathway that might participate in tumor pathogenesis.

Nuclea’s antibody is a rabbit anti-pan-MAPKAP antibody that recognizes any protein that is phosphorylated on the serine, threonine, or tyrosine residues. It can be used for both immunoprecipitations and Western Blots.

Receptor Pan-P13 Kinase Antibody

Nuclea has developed a specific, high-affinity antibody capable of binding the GRP1 pleckstrin homology (PH) domain to PIP3. PIP3 is a product of type I PI 3-kinase acting on its physiological substrate PIP2.

Nuclea’s antibody is a rabbit anti-pan-PI3 kinase antibody that recognizes any protein that is phosphorylated on the serine, threonine, or tyrosine residues. It can be used for both immunoprecipitations and Western Blots.

[  back to top  ]

 
 
© 2008 Nuclea Biotechnologies   |   design by Digizyme, Inc.